torcetrapib has been researched along with Dyslipidemias in 23 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 11 (47.83) | 29.6817 |
| 2010's | 12 (52.17) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Avorn, J; Franklin, JM; Hey, SP; Kesselheim, AS | 1 |
| Abdallah, M; Abi Rafeh, N; Bhat, T; El-Sayegh, S; Kalantar-Zadeh, K; Khoueiry, G; Lafferty, J; Raza, M; Saiful, F | 1 |
| Cai, J; Chen, C; Hu, Z; Li, C; Li, Y; Liu, L; Luo, H; Pei, F; Zeng, C; Zhang, W; Zhou, F; Zhou, L | 1 |
| Briand, F; Costard, C; Muzotte, E; Prunet-Marcassus, B; Sordello, S; Sulpice, T; Thieblemont, Q | 1 |
| Hermann, M; Ruschitzka, FT | 1 |
| Buckley, BM; Burgess, T; Capponi, AM; Kallend, D; Kastelein, JJ; Niesor, EJ; Stein, EA; Steiner, G; Stroes, ES | 1 |
| Bots, ML; Dogan, S; Duivenvoorden, R; Evans, GW; Grobbee, DE; Kastelein, JJ; Shear, CL; Visseren, FL | 1 |
| Athyros, VG; Katsiki, N; Mikhailidis, DP | 1 |
| Devaraj, S; Jialal, I | 1 |
| Barter, PJ; Boekholdt, SM; Breazna, A; Kastelein, JJ; Rye, KA; Tardif, JC; Waters, DD | 1 |
| André, A; Briand, F; Ouguerram, K; Sulpice, T; Thieblemont, Q | 1 |
| Shinkai, H | 1 |
| Briand, F; Muzotte, E; Sulpice, T; Thieblemont, Q | 1 |
| Angelin, B; Asztalos, BF; Björkhem, I; Brousseau, ME; Diffenderfer, MR; Digenio, AG; Mancuso, JP; Millar, JS; Nartsupha, C; Rader, DJ; Rudling, M; Schaefer, EJ; Welty, FK; Wolfe, ML | 1 |
| Zareba, G | 1 |
| Aronow, WS | 1 |
| Bots, ML; Duggan, WT; Evans, GW; Grobbee, DE; Kastelein, JJ; Revkin, JH; Riley, WA; Shear, CL; Tegeler, CH; Vicari, RM; Visseren, FL | 1 |
| El Harchaoui, K; Kastelein, JJ; Stroes, ES; van der Steeg, WA | 1 |
| Duriez, P | 2 |
| Suckling, K | 1 |
| Chapman, MJ; Guérin, M; Kontush, A | 1 |
7 review(s) available for torcetrapib and Dyslipidemias
| Article | Year |
|---|---|
Success, Failure, and Transparency in Biomarker-Based Drug Development: A Case Study of Cholesteryl Ester Transfer Protein Inhibitors.
Topics: Amides; Anticholesteremic Agents; Benzodiazepines; Biomarkers, Pharmacological; Cholesterol Ester Transfer Proteins; Drug Approval; Drug Discovery; Dyslipidemias; Endpoint Determination; Esters; Humans; Lipids; Oxazolidinones; Predictive Value of Tests; Quinolines; Reproducibility of Results; Sulfhydryl Compounds; Time Factors; Treatment Outcome | 2017 |
High-density lipoprotein in uremic patients: metabolism, impairment, and therapy.
Topics: Acetamides; Acetates; Acetyl-CoA C-Acetyltransferase; Anti-Inflammatory Agents; Anticholesteremic Agents; Antioxidants; Apolipoprotein A-I; Atherosclerosis; Cholesterol; Cholesterol Ester Transfer Proteins; Dyslipidemias; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Lipoproteins, HDL; Niacin; PPAR alpha; Quinolines; Renal Insufficiency, Chronic; Sulfonamides; Sulfonic Acids; Uremia | 2014 |
Cholesteryl ester transfer protein inhibitors in the treatment of dyslipidemia: a systematic review and meta-analysis.
Topics: Adult; Amides; Anticholesteremic Agents; Benzodiazepines; Blood Pressure; Cholesterol; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Cholesterol, LDL; Drug Therapy, Combination; Dyslipidemias; Esters; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Oxazolidinones; Quinolines; Randomized Controlled Trials as Topic; Sulfhydryl Compounds; Treatment Outcome; Triglycerides | 2013 |
The hypertension peril: lessons from CETP inhibitors.
Topics: Anticholesteremic Agents; Cholesterol Ester Transfer Proteins; Dyslipidemias; Humans; Hypertension; Quinolines | 2009 |
Cholesteryl ester transfer-protein modulator and inhibitors and their potential for the treatment of cardiovascular diseases.
Topics: Amides; Animals; Biomarkers; Cardiovascular Diseases; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Cholesterol, LDL; Dyslipidemias; Esters; Humans; Hypolipidemic Agents; Oxazolidinones; Quinolines; Sulfhydryl Compounds; Treatment Outcome | 2012 |
The role of CETP inhibition in dyslipidemia.
Topics: Amides; Anticholesteremic Agents; Cholesterol Ester Transfer Proteins; Clinical Trials as Topic; Dyslipidemias; Esters; Female; Humans; Hyperlipoproteinemia Type II; Hypertriglyceridemia; Male; Quinolines; Sulfhydryl Compounds | 2007 |
Spotlight on HDL-raising therapies: insights from the torcetrapib trials.
Topics: Aldosterone; Anticholesteremic Agents; Blood Pressure; Cardiovascular Diseases; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Clinical Trials as Topic; Dyslipidemias; Humans; Hypertension; Quinolines | 2008 |
6 trial(s) available for torcetrapib and Dyslipidemias
| Article | Year |
|---|---|
Safety and tolerability of dalcetrapib.
Topics: Amides; Anticholesteremic Agents; Cholesterol Ester Transfer Proteins; Coronary Artery Disease; Double-Blind Method; Dyslipidemias; Esters; Female; Humans; Incidence; Male; Middle Aged; Quinolines; Risk Assessment; Risk Factors; Sulfhydryl Compounds | 2009 |
Ultrasound protocols to measure carotid intima-media thickness in trials; comparison of reproducibility, rate of progression, and effect of intervention in subjects with familial hypercholesterolemia and subjects with mixed dyslipidemia.
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Carotid Artery, Internal; Disease Progression; Dyslipidemias; Female; Heptanoic Acids; Humans; Hyperlipoproteinemia Type II; Male; Middle Aged; Pyrroles; Quinolines; Randomized Controlled Trials as Topic; Reproducibility of Results; Tunica Intima; Ultrasonography | 2010 |
Effect of torcetrapib on glucose, insulin, and hemoglobin A1c in subjects in the Investigation of Lipid Level Management to Understand its Impact in Atherosclerotic Events (ILLUMINATE) trial.
Topics: Aged; Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Blood Glucose; Cholesterol, HDL; Diabetes Mellitus, Type 2; Dyslipidemias; Female; Glycated Hemoglobin; Heptanoic Acids; Homeostasis; Humans; Hyperglycemia; Hypoglycemic Agents; Insulin; Insulin Resistance; Male; Middle Aged; Prospective Studies; Pyrroles; Quinolines | 2011 |
Effects of cholesteryl ester transfer protein inhibition on high-density lipoprotein subspecies, apolipoprotein A-I metabolism, and fecal sterol excretion.
Topics: Anticholesteremic Agents; Apolipoprotein A-I; Atorvastatin; Bile Acids and Salts; Carrier Proteins; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Cohort Studies; Drug Therapy, Combination; Dyslipidemias; Feces; Glycoproteins; Heptanoic Acids; Humans; Pyrroles; Quinolines; Sterols | 2005 |
Torcetrapib and carotid intima-media thickness in mixed dyslipidaemia (RADIANCE 2 study): a randomised, double-blind trial.
Topics: Anticholesteremic Agents; Atorvastatin; Blood Pressure; Carotid Arteries; Cholesterol; Double-Blind Method; Dyslipidemias; Female; Heptanoic Acids; Humans; Male; Middle Aged; Pyrroles; Quinolines; Tunica Intima | 2007 |
CETP inhibition.
Topics: Anticholesteremic Agents; Blood Pressure; Cardiovascular Diseases; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Cholesterol, LDL; Double-Blind Method; Dyslipidemias; Humans; Quinolines | 2007 |
10 other study(ies) available for torcetrapib and Dyslipidemias
| Article | Year |
|---|---|
Raising HDL with CETP inhibitor torcetrapib improves glucose homeostasis in dyslipidemic and insulin resistant hamsters.
Topics: AMP-Activated Protein Kinases; Animals; Anticholesteremic Agents; Apolipoprotein A-I; Apolipoproteins E; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Cricetinae; Deoxyglucose; Diet, Atherogenic; Disease Models, Animal; Drug Evaluation, Preclinical; Dyslipidemias; Enzyme Activation; Feces; Glucose; Homeostasis; Hyperglycemia; Insulin Resistance; Male; Mesocricetus; Muscle, Skeletal; Quinolines; Random Allocation; Species Specificity | 2014 |
Trial watch: hope renewed for strategy to raise HDL cholesterol.
Topics: Anticholesteremic Agents; Cardiovascular Diseases; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Clinical Trials, Phase II as Topic; Dyslipidemias; Humans; Oxazolidinones; Quinolines; Risk Factors | 2011 |
The DEFINE study: a bright future for CETP inhibitors?
Topics: Animals; Anticholesteremic Agents; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Cholesterol, LDL; Dyslipidemias; Humans; Oxazolidinones; Quinolines | 2011 |
Novel cholesteryl ester transfer protein inhibitors: promising therapy for dyslipidemia?
Topics: Cholesterol Ester Transfer Proteins; Drugs, Investigational; Dyslipidemias; Humans; Hypolipidemic Agents; Molecular Targeted Therapy; Oxazolidinones; Quinolines | 2011 |
CETP inhibitor torcetrapib promotes reverse cholesterol transport in obese insulin-resistant CETP-ApoB100 transgenic mice.
Topics: Animals; Anticholesteremic Agents; Apolipoprotein B-100; Bile Acids and Salts; Biological Transport; Body Weight; Cells, Cultured; Cholesterol; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Dyslipidemias; Humans; Insulin Resistance; Lipoproteins; Macrophages; Male; Mice; Mice, Transgenic; Obesity; Quinolines | 2011 |
Upregulating reverse cholesterol transport with cholesteryl ester transfer protein inhibition requires combination with the LDL-lowering drug berberine in dyslipidemic hamsters.
Topics: Animals; Berberine; Biological Transport; Cholesterol; Cholesterol Ester Transfer Proteins; Cholesterol Esters; Cholesterol, HDL; Cholesterol, LDL; Cricetinae; Disease Models, Animal; Down-Regulation; Drug Therapy, Combination; Dyslipidemias; Feces; Hypolipidemic Agents; Kinetics; Lipoproteins, LDL; Liver; Liver X Receptors; Macrophages; Male; Mesocricetus; Orphan Nuclear Receptors; Quinolines; Up-Regulation | 2013 |
Torcetrapib and atorvastatin: a novel combination therapy for dyslipidemia.
Topics: Animals; Atorvastatin; Cholesterol, HDL; Drug Therapy, Combination; Dyslipidemias; Heptanoic Acids; Humans; Pyrroles; Quinolines | 2006 |
Intensive statin treatment or combination therapy in high-risk patients.
Topics: Drug Therapy, Combination; Dyslipidemias; Fenofibrate; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Quinolines; Risk Factors | 2007 |
The ENHANCE Study: an unusual publication of trial data raises questions beyond ezetimibe.
Topics: Anticholesteremic Agents; Atherosclerosis; Azetidines; Biomarkers; Cholesterol, HDL; Cholesterol, LDL; Controlled Clinical Trials as Topic; Drug Design; Dyslipidemias; Ezetimibe; Humans; Quinolines | 2008 |
Treating high-density lipoprotein cholesterol: a return to inhibition of cholesteryl ester transfer protein?
Topics: Anticholesteremic Agents; Atherosclerosis; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Cholesterol, LDL; Dyslipidemias; Heart Diseases; Humans; Oxazolidinones; Quinolines; Risk Factors | 2008 |